<DOC>
	<DOCNO>NCT01066351</DOCNO>
	<brief_summary>The purpose study demonstrate efficacy erythropoietin prevention acute kidney injury CKD patient undergo cardiac surgery .</brief_summary>
	<brief_title>Efficacy Erythropoietin Prevent Acute Kidney Injury Chronic Kidney Disease Patients Undergoing Cardiac Surgery</brief_title>
	<detailed_description>Acute kidney injury ( AKI ) occur 7.7-42 % cardiac surgery . The incidence AKI require renal replacement therapy follow coronary artery bypass grafting ( CABG ) surgery 0.7-3.5 % increase mortality rate . Erythropoietin ( EPO ) consider novel anti-apoptotic anti-inflammatory action . The present study design evaluate administration EPO mean prevent AKI patient .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>age &gt; 18 year . serum creatinine level &gt; 1.2 mg/dL baseline creatinine clearance level &lt; 60 mL/min ( measure recent sample , drawn within 2 month prior begin study ) patient need cardiac surgery patient acute kidney injury end stage renal disease ( require dialysis ) unstable renal function ( evidenced change serum creatinine &gt; 0.5 mg/dL , &gt; 25 % , within 14 day prior study ) allergy erythropoietin suffer congestive heart failure , cardiogenic shock emergent cardiac surgery . receive erythropoietin within 14 day study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>acute kidney injury</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>cardiac surgery</keyword>
</DOC>